The Effect of Food on the Pharmacokinetics of LY2140023 and LY404039 in Healthy Subjects After Administration of the Commercial Tablet Formulation of LY2140023
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Pomaglumetad methionil (Primary)
- Indications Schizophrenia
- Focus Pharmacokinetics
- Sponsors Denovo Biopharma; Eli Lilly and Company
- 29 Aug 2012 Status changed from not yet recruiting to withdrawn prior to recruitment.
- 14 Aug 2012 New trial record